BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) was the recipient of a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 1,200,000 shares, an increase of 10.1% from the May 15th total of 1,090,000 shares. Based on an average daily trading volume, of 781,100 shares, the days-to-cover ratio is currently 1.5 days.

Institutional Trading of BioVie

Several institutional investors have recently modified their holdings of the business. CVI Holdings LLC bought a new stake in BioVie during the first quarter valued at $317,000. Sheaff Brock Investment Advisors LLC raised its holdings in shares of BioVie by 276.9% during the first quarter. Sheaff Brock Investment Advisors LLC now owns 51,400 shares of the company’s stock valued at $27,000 after purchasing an additional 37,762 shares during the period. Finally, Jump Financial LLC acquired a new position in shares of BioVie during the third quarter valued at about $34,000. Institutional investors own 4.59% of the company’s stock.

BioVie Stock Performance

NASDAQ BIVI opened at $0.45 on Wednesday. The firm’s fifty day moving average price is $0.48 and its two-hundred day moving average price is $0.87. The stock has a market cap of $27.39 million, a PE ratio of -0.48 and a beta of 0.77. BioVie has a fifty-two week low of $0.41 and a fifty-two week high of $6.31.

BioVie (NASDAQ:BIVI) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.20) earnings per share for the quarter. As a group, sell-side analysts predict that BioVie will post -0.84 earnings per share for the current fiscal year.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.